These can deplete your bodys fluid and electrolyte balance, leading to dehydration
Retatrutide Retatrutide is a peptide therapy designed to aid in weight loss and metabolic health by targeting three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
More serious risks, though rare, include accidental injection into a blood vessel, which may cause skin damage, severe pain, or vision changesseek immediate medical attention if these occur
Research published in the New England Journal of Medicine (Wilding et al., 2021) showed that semaglutide at the 2.4mg weekly dose produced average weight loss of nearly 15 percent of body weight over 68 weeks
TL;DR Diarrhea affects 8-30% of Ozempic users, typically peaking during weeks 1-4 of treatment
How GLP-1 growth could affect other industries With this growth in supply, pharmaceutical companies and investors have taken note